Long-Term Outcomes of Ketamine Tablet Therapy

One of the most important questions in ketamine therapy is not "does it work?" but "how long does it work, and is it safe over extended periods?" Long-term outcome data for ketamine tablet is still emerging, but several studies have followed patients for 6 months to more than a year, providing meaningful early answers.

Why Long-Term Data Matters

Most clinical trials measure outcomes over weeks to months. This is sufficient to establish that a treatment works but insufficient to answer practical questions that matter most to patients and prescribers:

• Will the antidepressant response last without continued treatment?
• If continued treatment is needed, does ketamine tablet remain effective over years? (See also: what if ketamine tablet stops working)
• What are the safety risks with months or years of exposure?
• Does tolerance develop, requiring dose escalation?
• Are there signs of dependence or withdrawal?

Long-term studies for ketamine tablet are limited by the relative recency of widespread ketamine tablet use, the challenges of follow-up in this population (who often have severe, chronic illness), and the diversity of protocols used. Nevertheless, the available data provides important guidance.

Durability of Antidepressant Response

The Relapse Challenge

The most consistent finding in ketamine research across all routes is that antidepressant effects are not permanent without continued treatment. In IV ketamine trials, the majority of responders relapse within 2 to 4 weeks after stopping treatment. This pattern — rapid response, relatively rapid relapse — has been a major challenge in ketamine psychiatry.

Does ketamine tablet perform better or worse on this dimension?

Findings from Follow-Up Studies

Glue et al. (2020) — 6-Month Follow-Up

Paul Glue's New Zealand research group followed ketamine tablet responders for 6 months in an open-label extension study. Key findings:

• Patients who responded to the initial ketamine tablet course maintained antidepressant response through 6 months when continued on maintenance ketamine tablet
• Among patients who stopped ketamine tablet after initial response, approximately 50–60% relapsed within 4–8 weeks
• Maintenance dosing (once or twice weekly) was effective at sustaining response in most patients who required it

Lara et al. — Extended Follow-Up Case Series

In extended follow-up of the original Lara cohort (patients treated with daily ketamine tablet for 21 days), some patients maintained partial benefit for up to 3 months after stopping, while others relapsed more quickly. This suggests individual variability in the durability of ketamine's neuroplastic effects.

Telehealth Platform Registry Data

Emerging registry data from large telehealth ketamine platforms (collected from thousands of patients) provides real-world effectiveness data. Early reports from several major platforms suggest that:

• Patients who engage in ongoing ketamine therapy (monthly or bimonthly sessions) maintain response at 6- and 12-month assessments
• Patients who discontinue treatment have relapse rates consistent with clinical trial predictions
• Some patients report sustained remission even after treatment discontinuation, though this appears to be a minority

These data are observational and subject to selection bias but represent the largest real-world ketamine tablet datasets available.

Safety Over Time: What Long-Term Studies Show

Cognitive Effects

Perhaps the most common long-term safety concern expressed by patients and clinicians is cognitive impairment. Ketamine acutely affects cognition — but do these effects persist with long-term therapy?

Available evidence suggests:

• Acute cognitive effects: Documented and predictable; resolve within hours of a dose in most patients
• Persistent cognitive effects at therapeutic doses: Limited evidence of significant persistent impairment in patients using therapeutic doses; most long-term studies show no significant cognitive decline on standardized testing
• High-dose or heavy recreational use: Strong evidence of cognitive impairment; not applicable to therapeutic protocols

One long-term study from New Zealand followed patients on ketamine tablet for up to 12 months and found no significant changes in standard cognitive assessments compared to baseline — with the caveat that depressive cognition itself was also improving (depression causes cognitive impairment that remits with treatment, which can mask or offset any drug-related effects).

Urological Safety

Ketamine cystitis — a potentially serious condition involving inflammation and fibrosis of the bladder — is well-documented in recreational ketamine users at much higher doses and frequencies than therapeutic protocols. The risk at therapeutic oral doses appears substantially lower but is not zero:

• Most reported cases of ketamine cystitis involve doses of >100 mg/day in recreational users
• Therapeutic oral doses of 50–300 mg/day are significantly lower than recreational patterns
• Published case reports of bladder problems in therapeutic ketamine tablet users are rare but exist
• Long-term studies following therapeutic ketamine tablet patients have not documented significant urological toxicity in most cohorts

Practical recommendation: Urological monitoring (annual urinalysis, symptom screening) for patients on chronic ketamine tablet therapy at therapeutic doses is prudent even though the risk is lower than recreational use.

Cardiovascular Safety Over Time

Blood pressure and heart rate elevations are documented with each dose of ketamine. Long-term studies have generally found that:

• Cardiovascular effects do not worsen over time at therapeutic doses
• No cumulative cardiovascular toxicity has been documented in therapeutic populations
• Patients with pre-existing cardiovascular disease require ongoing blood pressure monitoring

Dependence and Abuse Potential

Ketamine's Schedule III classification reflects recognized abuse potential. Long-term clinical programs have documented:

• Physical dependence: Mild withdrawal symptoms (anxiety, depression, craving) occur in some patients who abruptly discontinue after extended use at higher doses
• Psychological dependence: Some patients express strong preference for continued ketamine treatment; distinguishing appropriate response to effective treatment from psychological dependence requires clinical judgment
• Dose escalation: Most patients in therapeutic programs do not exhibit escalating dose requirements over time; some require modest dose adjustments during maintenance

Patients who have prior history of ketamine abuse or other substance use disorders require closer monitoring for escalating use.

Dose Stability Over Long-Term Treatment

A clinically important question is whether tolerance develops — requiring progressively higher doses to maintain the same antidepressant effect.

Available data suggests:

• Most patients maintain response at stable doses for months to years without requiring dose escalation
• Some patients require modest dose adjustments (typically 10–30% increases) over extended treatment
• True tachyphylaxis (complete loss of response at any dose) does occur but appears uncommon in properly selected patients
• Occasional "drug holidays" (structured breaks from treatment) have been explored as a strategy to restore responsiveness, though evidence is limited

The Maintenance Ketamine Model

The emerging clinical consensus is that for many patients with treatment-resistant depression, ketamine tablet functions more like a maintenance medication than a curative treatment — similar to how patients with bipolar disorder maintain mood stabilizers indefinitely rather than expecting a permanent cure.

This has important implications for long-term outcomes research: the goal is not "how long does response last after stopping ketamine?" but "how well can response be maintained with appropriate ongoing treatment?"

The data, though still developing, suggests that ongoing maintenance ketamine tablet can sustain antidepressant response in the majority of responders — and that the treatment remains safe over at least 6–12 months of follow-up in published studies.

Research Gaps and Future Studies

Critical long-term questions still awaiting better evidence:

• Does sustained ketamine tablet use modify the long-term course of treatment-resistant depression (are patients achieving remission that outlasts the drug?)
• What are the optimal maintenance dosing frequencies over years?
• Are there predictable patient characteristics that identify who will sustain long-term remission?
• What happens to bladder health in patients on therapeutic ketamine tablet for 3–5+ years?

These questions will be answered as the field matures and larger, longer-duration studies are completed.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service